vs
Side-by-side financial comparison of CorMedix Inc. (CRMD) and STURM RUGER & CO INC (RGR). Click either name above to swap in a different company.
STURM RUGER & CO INC is the larger business by last-quarter revenue ($151.1M vs $128.6M, roughly 1.2× CorMedix Inc.). CorMedix Inc. produced more free cash flow last quarter ($92.7M vs $12.3M).
CorMedix Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing novel therapeutic products for the prevention and treatment of infectious, inflammatory and cardiorenal diseases. Its lead candidate targets catheter-related bloodstream infections, serving critical care and chronic dialysis patient populations primarily across North America and European markets.
Sturm, Ruger & Company, Inc., better known by the shortened name Ruger, is an American firearm manufacturing company based in Southport, Connecticut, with production facilities also in Newport, New Hampshire; Mayodan, North Carolina; and Prescott, Arizona. The company was founded in 1949 by Alexander McCormick Sturm and William B. Ruger and has been publicly traded since 1969.
CRMD vs RGR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $128.6M | $151.1M |
| Net Profit | — | — |
| Gross Margin | 83.4% | 17.8% |
| Operating Margin | 46.0% | 2.3% |
| Net Margin | — | — |
| Revenue YoY | — | 3.6% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.20 | $0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $128.6M | $151.1M | ||
| Q3 25 | $104.3M | $126.8M | ||
| Q2 25 | $39.7M | $132.5M | ||
| Q1 25 | $39.1M | $135.7M | ||
| Q4 24 | — | $145.8M | ||
| Q3 24 | — | $122.3M | ||
| Q2 24 | — | $130.8M | ||
| Q1 24 | — | $136.8M |
| Q4 25 | — | — | ||
| Q3 25 | $108.6M | $1.6M | ||
| Q2 25 | $19.8M | $-17.2M | ||
| Q1 25 | $20.6M | $7.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $4.7M | ||
| Q2 24 | — | $8.3M | ||
| Q1 24 | — | $7.1M |
| Q4 25 | 83.4% | 17.8% | ||
| Q3 25 | 89.3% | 15.1% | ||
| Q2 25 | 95.3% | 3.9% | ||
| Q1 25 | 95.9% | 22.0% | ||
| Q4 24 | — | 22.8% | ||
| Q3 24 | — | 18.5% | ||
| Q2 24 | — | 22.3% | ||
| Q1 24 | — | 21.5% |
| Q4 25 | 46.0% | 2.3% | ||
| Q3 25 | 49.2% | -2.7% | ||
| Q2 25 | 49.2% | -15.6% | ||
| Q1 25 | 51.5% | 6.2% | ||
| Q4 24 | — | 7.8% | ||
| Q3 24 | — | 3.1% | ||
| Q2 24 | — | 6.9% | ||
| Q1 24 | — | 5.5% |
| Q4 25 | — | — | ||
| Q3 25 | 104.1% | 1.2% | ||
| Q2 25 | 49.9% | -13.0% | ||
| Q1 25 | 52.8% | 5.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.9% | ||
| Q2 24 | — | 6.3% | ||
| Q1 24 | — | 5.2% |
| Q4 25 | $0.20 | $0.22 | ||
| Q3 25 | $1.26 | $0.10 | ||
| Q2 25 | $0.28 | $-1.05 | ||
| Q1 25 | $0.30 | $0.46 | ||
| Q4 24 | — | $0.62 | ||
| Q3 24 | — | $0.28 | ||
| Q2 24 | — | $0.47 | ||
| Q1 24 | — | $0.40 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $148.5M | $92.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $405.3M | $283.8M |
| Total Assets | $826.1M | $342.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $148.5M | $92.5M | ||
| Q3 25 | $55.7M | $80.8M | ||
| Q2 25 | $190.7M | $101.4M | ||
| Q1 25 | $77.5M | $108.3M | ||
| Q4 24 | — | $105.5M | ||
| Q3 24 | — | $96.0M | ||
| Q2 24 | — | $105.6M | ||
| Q1 24 | — | $115.3M |
| Q4 25 | $405.3M | $283.8M | ||
| Q3 25 | $374.1M | $279.6M | ||
| Q2 25 | $220.6M | $289.3M | ||
| Q1 25 | $114.9M | $321.5M | ||
| Q4 24 | — | $319.6M | ||
| Q3 24 | — | $314.9M | ||
| Q2 24 | — | $321.5M | ||
| Q1 24 | — | $332.0M |
| Q4 25 | $826.1M | $342.0M | ||
| Q3 25 | $750.9M | $342.3M | ||
| Q2 25 | $252.6M | $349.5M | ||
| Q1 25 | $149.6M | $379.0M | ||
| Q4 24 | — | $384.0M | ||
| Q3 24 | — | $373.5M | ||
| Q2 24 | — | $376.7M | ||
| Q1 24 | — | $385.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $94.5M | $15.5M |
| Free Cash FlowOCF − Capex | $92.7M | $12.3M |
| FCF MarginFCF / Revenue | 72.1% | 8.2% |
| Capex IntensityCapex / Revenue | 1.3% | 2.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $172.8M | $38.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $94.5M | $15.5M | ||
| Q3 25 | $30.9M | $12.9M | ||
| Q2 25 | $30.0M | $14.7M | ||
| Q1 25 | $19.7M | $11.1M | ||
| Q4 24 | — | $20.0M | ||
| Q3 24 | — | $9.4M | ||
| Q2 24 | — | $18.7M | ||
| Q1 24 | — | $7.3M |
| Q4 25 | $92.7M | $12.3M | ||
| Q3 25 | $30.4M | $7.0M | ||
| Q2 25 | $30.0M | $9.1M | ||
| Q1 25 | $19.7M | $10.0M | ||
| Q4 24 | — | $16.4M | ||
| Q3 24 | — | $2.6M | ||
| Q2 24 | — | $10.1M | ||
| Q1 24 | — | $5.6M |
| Q4 25 | 72.1% | 8.2% | ||
| Q3 25 | 29.1% | 5.5% | ||
| Q2 25 | 75.4% | 6.9% | ||
| Q1 25 | 50.5% | 7.4% | ||
| Q4 24 | — | 11.2% | ||
| Q3 24 | — | 2.1% | ||
| Q2 24 | — | 7.7% | ||
| Q1 24 | — | 4.1% |
| Q4 25 | 1.3% | 2.1% | ||
| Q3 25 | 0.5% | 4.6% | ||
| Q2 25 | 0.1% | 4.2% | ||
| Q1 25 | 0.0% | 0.8% | ||
| Q4 24 | — | 2.5% | ||
| Q3 24 | — | 5.5% | ||
| Q2 24 | — | 6.6% | ||
| Q1 24 | — | 1.3% |
| Q4 25 | — | — | ||
| Q3 25 | 0.28× | 8.15× | ||
| Q2 25 | 1.51× | — | ||
| Q1 25 | 0.96× | 1.43× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | — | 2.27× | ||
| Q1 24 | — | 1.04× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CRMD
| Acquisition Of Melinta | $52.9M | 41% |
| Melinta Portfolio | $45.5M | 35% |
| Other | $18.6M | 14% |
| Contract Revenue | $7.4M | 6% |
| BARDA Agreement | $4.2M | 3% |
RGR
| Firearms | $150.6M | 100% |
| Castings | $7.3M | 5% |
